Table 1.
Variables | n | % |
---|---|---|
ER |
|
|
Negative |
14 |
51.9% |
Positive |
9 |
33.3% |
Unknown |
4 |
14.8% |
PR |
|
|
Negative |
18 |
66.7% |
Positive |
5 |
18.5% |
Unknown |
4 |
14.8% |
Run-in Treatment |
|
|
Trastuzumab |
17 |
63.0% |
Nab-paclitaxel |
10 |
37.0% |
Response |
|
|
PathCR |
13 |
48.1% |
No PathCR |
10 |
37.0% |
Unknown | 4 | 14.8% |